Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
Michael Hill lifts full-year revenue as it shifts focus back to core namesake brand

2018-07-10 nzherald.co.nz
Michael Hill International increased revenue 3.3 per cent in its 2018 fiscal year as it opened more namesake brand stores in Australia and Canada, exited its US operations and began the closure of its Emma & Roe chain.
MHI MXRHY MXRHF

11
Shares rise after bumpy week, led by NZ Refining

2018-06-22 nzherald.co.nz
New Zealand shares rose, led by New Zealand Refining Company and Synlait Milk while Port of Tauranga and A2 Milk Co fell.
PPL FBU PUPKY MHI FCREY MXRHY NZR FRCEF SKT SYKWF PPSHY FBU SKKTY SML MXRHF

0
Michael Hill Jeweller pulls plug on low-cost brand

2018-06-22 radionz.co.nz
Jewellery retailer Michael Hill International will close its remaining Emma and Roe shops and concentrate on its core brand.
MHI MXRHY MXRHF

0
Michael Hill to close last Emma & Roe stores

2018-06-21 nzherald.co.nz
Michael Hill International said it plans to close the remaining six stores of its Emma & Roe chain as well as the sub-brand's online business.
MHI MXRHY MXRHF

11
A2 to join MSCI main stock index as Mercury drops off

2018-05-14 nzherald.co.nz
A review of global stock indices by MSCI will, as expected, add A2 Milk to the international investment advisor's main global index, with Mercury New Zealand to be removed.
BGR FBU MHI FBU THL FCREY MXRHY FRCEF MXRHF SML

11
Fletcher gains as stock stays in MSCI main index

2018-05-14 nzherald.co.nz
A review of global stock indices by MSCI has seen Fletcher Building shares gain after news the stock will remain on the international investment adviser's main global index, with A2 Milk rising on its planned entry and Mercury New Zealand dipping due to its planned removal.
BGR FBU MHI FBU THL FCREY MXRHY FRCEF MXRHF SML

1
Exit from US jewellery business to cost Michael Hill $6m

2018-04-11 nzherald.co.nz
Michael Hill International said the exit from its US business is expected to cost US$4.5 million (NZ$6.1 million) for lease terminations and employee severance costs after it was unable to find a buyer for the jewellery stores.
MHI MXRHY MXRHF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to NZX:MHI / Michael Hill International on message board site Silicon Investor.

AMHI - American HealthChoice, Inc. UMHI - Universal Media Holdings, Inc.